Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children who are at high-risk of RSV disease. All enrolled participants will receive palivizumab 15 mg/kg IM injection once a month for up to 5 injections during the study. Children who undergo cardiac surgery with cardiopulmonary bypass during the study should receive an additional dose of study intervention immediately after surgery, when medically stable for IM injection as determined by the physician. Prior to each study intervention administration, all participants will undergo safety assessments. A follow-up visit will be performed telephonically with the parent(s) or legal guardian(s) of all participants 30 days after their last injection of palivizumab.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Respiratory Syncytial Virus (RSV)

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Research Site, Hyderabad, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants at risk of severe RSV disease defined as fulfilling at least one of the following:

Infants born ≤ 35 wGA and are < 6 months of age at enrolment.
Children < 24 months of age at enrolment and requiring treatment for BPD within the last 6 months.
Children < 24 months of age and with haemodynamically significant CHD.
Written informed consent obtained from the participant's parent(s)/legal guardian and the participant's parent(s)/legal guardian is able to understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

Hospitalisation at the time of enrolment, unless the discharge is expected within 30 days of the time of enrolment
Required mechanical ventilation (including continuous positive airway pressure) or other mechanical respiratory or cardiac support at the time of enrolment.
Anticipated cardiac surgery within 2 weeks after enrolment.
Anticipated survival of < 6 months after enrolment in the trial.
Active LRTD, including RSV infection at the time of enrolment and/or study intervention administration.
Any fever (≥ 38.0°C) or acute illness within 7 days prior to investigational product administration.
Known history of evolving or unstable neurologic disorder.
Known history of unstable cardiac or respiratory status, including cardiac defects so severe that survival is not expected or for which cardiac transplantation is planned or anticipated.
Known allergy, including to immunoglobulin products, or history of allergic reaction.
Receipt of palivizumab or other RSV monoclonal antibodies or any RSV vaccine, including maternal RSV vaccination.
Receipt of any monoclonal or polyclonal antibody (for example, hepatitis B immune globulin, intravenous immunoglobulin) or anticipated use during the study.
Concurrent enrolment in another interventional study.
Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
Judgment by the investigator that the participant should not participate in the study if the participant or the participant's parent/legal guardian is unlikely to comply with study procedures, restrictions, and requirements.

Treatment and study plan

Palivizumab 15 mg/kg

Drug

Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection

Primary outcomes

To assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months).

Time frame: screening to day 151
- To determine percentage of participants with AEs and SAEs. 2) To assess nature, incidence, and severity of all AEs including unexpected adverse drug reactions 2)To determine percentage of participants with AEs that lead to study intervention discontinuation.

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Acronym: Synagis

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Feb 28, 2025
Registry last updated: Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting